285 related articles for article (PubMed ID: 33461211)
1. The Card1 nuclease provides defence during type III CRISPR immunity.
Rostøl JT; Xie W; Kuryavyi V; Maguin P; Kao K; Froom R; Patel DJ; Marraffini LA
Nature; 2021 Feb; 590(7847):624-629. PubMed ID: 33461211
[TBL] [Abstract][Full Text] [Related]
2. Ring nucleases deactivate type III CRISPR ribonucleases by degrading cyclic oligoadenylate.
Athukoralage JS; Rouillon C; Graham S; Grüschow S; White MF
Nature; 2018 Oct; 562(7726):277-280. PubMed ID: 30232454
[TBL] [Abstract][Full Text] [Related]
3. Activation and self-inactivation mechanisms of the cyclic oligoadenylate-dependent CRISPR ribonuclease Csm6.
Garcia-Doval C; Schwede F; Berk C; Rostøl JT; Niewoehner O; Tejero O; Hall J; Marraffini LA; Jinek M
Nat Commun; 2020 Mar; 11(1):1596. PubMed ID: 32221291
[TBL] [Abstract][Full Text] [Related]
4. A Type III-B Cmr effector complex catalyzes the synthesis of cyclic oligoadenylate second messengers by cooperative substrate binding.
Han W; Stella S; Zhang Y; Guo T; Sulek K; Peng-Lundgren L; Montoya G; She Q
Nucleic Acids Res; 2018 Nov; 46(19):10319-10330. PubMed ID: 30239876
[TBL] [Abstract][Full Text] [Related]
5. A cyclic oligonucleotide signaling pathway in type III CRISPR-Cas systems.
Kazlauskiene M; Kostiuk G; Venclovas Č; Tamulaitis G; Siksnys V
Science; 2017 Aug; 357(6351):605-609. PubMed ID: 28663439
[TBL] [Abstract][Full Text] [Related]
6. The CRISPR effector Cam1 mediates membrane depolarization for phage defence.
Baca CF; Yu Y; Rostøl JT; Majumder P; Patel DJ; Marraffini LA
Nature; 2024 Jan; 625(7996):797-804. PubMed ID: 38200316
[TBL] [Abstract][Full Text] [Related]
7. Regulation of the RNA and DNA nuclease activities required for Pyrococcus furiosus Type III-B CRISPR-Cas immunity.
Foster K; Grüschow S; Bailey S; White MF; Terns MP
Nucleic Acids Res; 2020 May; 48(8):4418-4434. PubMed ID: 32198888
[TBL] [Abstract][Full Text] [Related]
8. A Type III CRISPR Ancillary Ribonuclease Degrades Its Cyclic Oligoadenylate Activator.
Athukoralage JS; Graham S; Grüschow S; Rouillon C; White MF
J Mol Biol; 2019 Jul; 431(15):2894-2899. PubMed ID: 31071326
[TBL] [Abstract][Full Text] [Related]
9. Structural basis of cyclic oligoadenylate degradation by ancillary Type III CRISPR-Cas ring nucleases.
Molina R; Jensen ALG; Marchena-Hurtado J; López-Méndez B; Stella S; Montoya G
Nucleic Acids Res; 2021 Dec; 49(21):12577-12590. PubMed ID: 34850143
[TBL] [Abstract][Full Text] [Related]
10. An anti-CRISPR viral ring nuclease subverts type III CRISPR immunity.
Athukoralage JS; McMahon SA; Zhang C; Grüschow S; Graham S; Krupovic M; Whitaker RJ; Gloster TM; White MF
Nature; 2020 Jan; 577(7791):572-575. PubMed ID: 31942067
[TBL] [Abstract][Full Text] [Related]
11. Csx3 is a cyclic oligonucleotide phosphodiesterase associated with type III CRISPR-Cas that degrades the second messenger cA
Brown S; Gauvin CC; Charbonneau AA; Burman N; Lawrence CM
J Biol Chem; 2020 Oct; 295(44):14963-14972. PubMed ID: 32826317
[TBL] [Abstract][Full Text] [Related]
12. The CRISPR ancillary effector Can2 is a dual-specificity nuclease potentiating type III CRISPR defence.
Zhu W; McQuarrie S; Grüschow S; McMahon SA; Graham S; Gloster TM; White MF
Nucleic Acids Res; 2021 Mar; 49(5):2777-2789. PubMed ID: 33590098
[TBL] [Abstract][Full Text] [Related]
13. Cyclic oligoadenylate signalling mediates Mycobacterium tuberculosis CRISPR defence.
Grüschow S; Athukoralage JS; Graham S; Hoogeboom T; White MF
Nucleic Acids Res; 2019 Sep; 47(17):9259-9270. PubMed ID: 31392987
[TBL] [Abstract][Full Text] [Related]
14. Regulation of cyclic oligoadenylate synthesis by the
Nasef M; Muffly MC; Beckman AB; Rowe SJ; Walker FC; Hatoum-Aslan A; Dunkle JA
RNA; 2019 Aug; 25(8):948-962. PubMed ID: 31076459
[TBL] [Abstract][Full Text] [Related]
15. CRISPR-Cas III-A Csm6 CARF Domain Is a Ring Nuclease Triggering Stepwise cA
Jia N; Jones R; Yang G; Ouerfelli O; Patel DJ
Mol Cell; 2019 Sep; 75(5):944-956.e6. PubMed ID: 31326273
[TBL] [Abstract][Full Text] [Related]
16. Structure and mechanism of a Type III CRISPR defence DNA nuclease activated by cyclic oligoadenylate.
McMahon SA; Zhu W; Graham S; Rambo R; White MF; Gloster TM
Nat Commun; 2020 Jan; 11(1):500. PubMed ID: 31980625
[TBL] [Abstract][Full Text] [Related]
17. Structural basis for the endoribonuclease activity of the type III-A CRISPR-associated protein Csm6.
Niewoehner O; Jinek M
RNA; 2016 Mar; 22(3):318-29. PubMed ID: 26763118
[TBL] [Abstract][Full Text] [Related]
18. The CRISPR-associated Csx1 protein of Pyrococcus furiosus is an adenosine-specific endoribonuclease.
Sheppard NF; Glover CV; Terns RM; Terns MP
RNA; 2016 Feb; 22(2):216-24. PubMed ID: 26647461
[TBL] [Abstract][Full Text] [Related]
19. Tetramerisation of the CRISPR ring nuclease Crn3/Csx3 facilitates cyclic oligoadenylate cleavage.
Athukoralage JS; McQuarrie S; Grüschow S; Graham S; Gloster TM; White MF
Elife; 2020 Jun; 9():. PubMed ID: 32597755
[TBL] [Abstract][Full Text] [Related]
20. The ribonuclease activity of Csm6 is required for anti-plasmid immunity by Type III-A CRISPR-Cas systems.
Foster K; Kalter J; Woodside W; Terns RM; Terns MP
RNA Biol; 2019 Apr; 16(4):449-460. PubMed ID: 29995577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
